Filing Flows › Vertex Pharmaceuticals (VRTX) › Net income
Vertex Pharmaceuticals (VRTX) net income by quarter
Vertex Pharmaceuticals' net income was $654M in Q3 2026 (third quarter 2026), -41% from Q2 2026. Over the last 7 quarters it ranged from $646M (Q1 2025) to $1.2B (Q4 2025).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $654M | -41% | -40% |
| Q2 2026 | $1.1B | +7% | +6% |
| Q1 2026 | $1.0B | -13% | +60% |
| Q4 2025 | $1.2B | +10% | — |
| Q3 2025 | $1.1B | +5% | — |
| Q2 2025 | $1.0B | +60% | — |
| Q1 2025 | $646M | — | — |
Q3 2026 at a glance
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vertex Pharmaceuticals' net income?
Vertex Pharmaceuticals' net income was $654M in Q3 2026 (third quarter 2026), -41% from Q2 2026.
How has Vertex Pharmaceuticals' net income changed?
Over the last 7 quarters it ranged from $646M (Q1 2025) to $1.2B (Q4 2025).
Q3 2026 results → · How Vertex Pharmaceuticals makes money →